GlobeNewswire by notified

Dynacor Reports Sales of $46.0 Million and a Quarterly Net Income of $0.8 Million in Q3-2022 (US$0.02 or CA$0.03 Per Share) With a Solid Cash in Hand of $31.0 Million

Share

MONTREAL, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Dynacor Group Inc. (TSX: DNG) (Dynacor or the Corporation) released its unaudited condensed interim consolidated financial statements and the management's discussion and analysis (MD&A) for the third quarter ended September 30, 2022.

These documents have been filed electronically with SEDAR at www.sedar.com and will be available on the Corporation's website www.dynacor.com.

(All figures in this press release are in Ms of US$ unless stated otherwise. All amounts per share are in US$. All variance % are calculated from rounded figures. Some additions might be incorrect due to rounding).

Q3-2022 OVERVIEW AND HIGHLIGHTS

OVERVIEW

Dynacor completed the three-month period ended September 30, 2022 (“Q3-2022”) with quarterly sales of $46.0 million and a net income of $0.8 million (US$0.02 per share) compared to sales of $61.9 million and a net income of $3.5 million (US$0.09 per share) for the third quarter of 2021 (“Q3-2021”). The 2022 third quarter financial results were below expectations due to lower ore grades delivered to the plant and lower market gold prices during the quarter.

While the plant continued operating at its 430 tpd capacity, the ore volume processed increased by 3.1% compared to Q3-2021. The sales decrease, compared to Q3-2021, is mainly explained by a 16.0% decrease in ore grades processed which affected our gold production and volume of gold sold. The Q3-2021 gold production was by far the 2021 highest quarter, due to higher-than-average grade of ore supplied.

Q3-2021 beneficiated as well from the $2.9 million sale of 1,600 ounces of gold which had been retained in December 2019 and released, for export and sale, in September 2021.

HIGHLIGHTS

Operational

  • Higher volume processed. The plant processed a volume of 37,410 tonnes of ore (407 tpd average) compared to 36,281 tonnes in Q3-2021 (394 tpd), a 3.1% increase;
  • Reduced gold production. In Q3-2022, gold equivalent production amounted to 27,252 AuEq ounces compared to 31,889 AuEq ounces in Q3-2021 a 14.5% decrease;
  • Increase ore inventories during the quarter. At the end of Q3, ore inventories amounted to over 9,000 tons of ore representing over 20 days of production.

Financial

  • Solid cash position. Cash on hand remained solid at $31.0 million at the end of Q3-2022 compared to $27.1 million at year end 2021 due to the cash generated by operating activities;
  • Decreased sales compared to Q3-2021. Due to lower volume produced and sold and lower average gold market price, sales amounted to $46.0 million in Q3-2022 compared to $61.9 million in Q3-2021;
  • Decreased in gross operating margin. Gross operating margin of $4.5 million (9.8% of sales) in Q3-2022, compared to $7.9 million (12.7% of sales) in Q3-2021 due to lower volume sold and decreasing gold prices during the period compared to an increasing trend in the comparative period;
  • Reduced operating income. Operating income of $3.2 million in Q3-2022 compared to $6.6 million in Q3-2021 due to the decrease in the gross margin;
  • Earning per share affected by reduced gross margin and increased tax expense. Dynacor recorded a net income of $0.8 million in Q3-2022 ($0.02 or CA$0.03 per share) compared to $3.5 million ($0.09 or CA$0.12 per share) in Q3-2021;
  • Decreased cash gross operating margin per AuEq ounce. Cash gross operating margin of $197 per AuEq ounce sold (1) compared to $242 in Q3-2021;
  • Decreased EBITDA. EBITDA (2) of $3.8 million, compared to $7.2 million in Q3-2021;
  • Decreased cash flows. Cash flows from operating activities before change in working capital items of $2.0 million ($0.05 per share) (3) compared to $4.4 million ($0.11 per share) in Q3-2021.

Return to Shareholders

  • Share buy-back. 213,655 common shares repurchased for $0.5 million (CA$0.6 million) in Q3-2022, compared to 59,914 common shares for $0.1 million (CA$0.2 million) in Q3-2021;
  • Increased dividends. Continuation of monthly dividend payments which had been increased by 25% at the start of 2022 to CA$0.10 per share per year which represented a 3.2% dividend yield based on the beginning of 2022 share price or 3.9% based on the share price at the end of Q3-2022.

(1) Cash gross operating margin per AuEq ounce is in US$ and is calculated by subtracting the average cash cost of sale per equivalent ounces of Au from the average selling price per equivalent ounces of Au and is a non-IFRS financial performance measure with no standard definition under IFRS. It is therefore possible that this measure could not be comparable with a similar measure of another company.

(2) EBITDA: “Earnings before interest, taxes and depreciation” is a non-IFRS financial performance measure with no standard definition under IFRS. It is therefore possible that this measure could not be comparable with a similar measure of another corporation. The Corporation uses this non-IFRS measure as an indicator of the cash generated by the operations and allows investor to compare the profitability of the Corporation with others by canceling effects of different assets basis, effects due to different tax structures as well as the effects of different capital structures.

(3) Cash-flow per share is a non-IFRS financial performance measure with no standard definition under IFRS. It is therefore possible that this measure could not be comparable with a similar measure of another corporation. The Corporation uses this non-IFRS measure which can also be helpful to investors as it provides a result which can be compared with the Corporation market share price.

RESULTS FROM OPERATIONS

Unaudited Consolidated Statement of net income and comprehensive income

Three-month periods
ended September 30,
Nine-month periods
ended September 30,
(in $'000) (unaudited)2022202120222021
Sales45,99861,941150,022145,627
Cost of sales(41,485)(54,075)(131,699)(125,941)
Gross operating margin 4,5137,86618,32319,686
General and administrative expenses(1,229)(1,224)(4,382)(4,434)
Other project expenses(104)-(209)(16)
Operating income 3,1806,64213,73215,236
Financial income and expenses64(77)(24)(185)
Foreign exchange loss(127)(80)(210)(371)
Income before income taxes3,1176,48513,49814,680
Current income tax expense(1,984)(2,695)(5,308)(6,084)
Deferred income tax (expense) recovery(332)(272)313(810)
Net income and comprehensive income8013,5188,5037,786
Earnings per share
Basic$0.02$0.09$0.22$0.20
Diluted$0.02$0.09$0.21$0.20

Total sales amounted to $46.0 million compared to $61.9 million in Q3-2021. The $15.9 million decrease is explained by lower quantities of gold ounces sold (-23.3% or -$14.4 million) due to the 16.0% decrease in ore grades compared to Q3-2021 which had the highest 2021 quarterly average grade and to the lower average gold price (-$1.5 million).

Cumulative nine-months sales increased by $4.4 million compared to last year with higher average prices and quantities sold contributing respectively to a $2.4 and $2.0 million increase.

The Q3-2022 gross operating margin amounted to $4.5 million (9.8% of sales) compared to $7.9 million (12.7% of sales) in Q3-2021. The Q3-2022 gross operating margin was negatively impacted by lower grades affecting our unit cost of production and by the unfavorable trend in gold market prices during the period compared to an opposite favorable trend in Q3-2021.

General and administrative expenses amounted to $1.2 million in Q3-2022 comparable to Q3-2021.

The Q3-2022 net income was also affected by the recording of a $2.3 million income tax expenses including $0.3 million of withholding tax paid on dividends received from the subsidiary and a $0.3 million (non-cash) deferred income tax expense. The deferred tax expense or recovery is mainly explained by the variance throughout the period of the Peruvian Sol against the US$ which affect long term assets local tax basis. Future fluctuations will affect positively or negatively the deferred tax at the end of each period.

Reconciliation of non-IFRS measures

(in $'000) (unaudited)Three-month periods
ended S
eptember 30,
Nine-month periods
ended S
eptember 30,
2022202120222021
Reconciliation of net income and comprehensive income to EBITDA
Net income and comprehensive income8013,5188,5037,786
Income tax expenses (current and deferred)2,3162,9684,9956,894
Financial expenses(64)7724185
Depreciation7996662,2691,957
EBITDA 3,8527,22915,79116,822

CONSOLIDATED CASH FLOW FROM OPERATING, INVESTING AND FINANCING ACTIVITIES AND WORKING CAPITAL AND LIQUIDITY

Operating activities

During Q3-2022, the cash flow from operations, before changes in working capital items, amounted to $2.0 million ($10.6 million for the nine-month period ending September 30, 2022), compared to $4.4 million in Q3-2021 ($10.6 million for the nine-month period ending September 30, 2021).

During Q3-2022, total cash from operating activities amounted to -$0.05 million ($9.5 million for the nine-month period ending September 30, 2022) compared to 5.7 million in Q3-2021 ($10.4 million for the nine-month period ending September 30, 2021). Changes in working capital items amounted to -$2.0 million (-$1.1 million for the nine-month period ending September 30, 2022) compared to $1.3 million in Q3-2021 (-$0.2 million for the nine-month period ending September 30, 2021). The variances are mainly attributable to the variances in inventories and accounts receivable.

Investing activities

During the three-month period ended September 30, 2022, the Corporation invested $0.7 million (cumulative nine-month 2022 of $2.5 million). These amounts are in line with last year and mainly include investments at the plant and new vehicles. All investments are financed with internally generated cash-flows.

Financing activities

In Q3-2022, monthly dividends totaling CA$0.025 per share were disbursed for a total consideration of $0.7 million (CA$1.0 million) (cumulative nine-month of CA$0.075). In Q3-2021, monthly dividends totaling CA$0.020 per share were disbursed for a total consideration of $0.6 million (CA$0.8 million). Increases in monthly dividend per share paid were attributed from June 2021 and then again from January 2022.  

In Q3-2022, 213,655 common shares were repurchased under the Corporation normal course issuer bid share buyback program for a total cash consideration of $0.5 million (CA$0.6 million) (cumulative nine-month of 589,851 shares) (59,914 shares for a total cash consideration of $0.1 million (CA$0.2 million) in Q3-2021).

In Q3-2022, the Corporation issued 21,250 common shares following the exercise of purchase options for a consideration of $0.03 million (CA$0.04 million) (cumulative nine-month of 515,930 shares) (54,914 shares for $0.1 million or CA$0.2 million in Q3-2021).

Working capital and liquidity

As at September 30, 2022, the Corporation’s working capital increased to $41.6 million, including $31.0 million in cash ($36.4 million, including $27.1 million in cash at December 31, 2021).

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at September 30, 2022, total assets amounted to $94.2 million ($91.4 million as at December 31, 2021). Major variances since last year-end come from the increase in cash and variances in working capital items.

(in $'000) (unaudited)As at
September 30,
As at
December 31,
20222021
Cash31,03927,099
Accounts receivable9,3968,407
Inventories12,24014,764
Property, plant and equipment21,12420,759
Right-of-use assets253341
Exploration and evaluation assets18,53818,516
Other assets1,6481,471
Total assets94,23891,357
Trade and other payables11,21811,680
Asset retirement obligations3,4943,553
Current tax liabilities1602,217
Deferred tax liabilities1,2421,555
Lease liabilities240343
Shareholders' equity77,88472,009
Total liabilities and equity94,23891,357

FOLLOW-UP OUTLOOK 2022

Ore processing

The decline in ore grades and recent gold prices impacted on the quarter sales.

For 2022, the Corporation maintains its forecasted sales in the range of $200-220 million representing a growth of 4-14% over 2021 sales which could have resulted in a net income in the range of $11-13 million ($0.28-0.33 per share (CA$0.36-0.42 per share). Forecasted sales were based on an additional increased capacity during 2022. This investment is underway as a result of a higher level of ore inventory. The achievement of forecasted sales will depend on the ore grade supplied, gold price and the capacity increase during the fourth quarter.

The Corporation is continuing to assess other opportunities of growth in Peru as well as in other jurisdictions.

(1)  Using opening 2022 market gold price of $1,800 per ounce

ABOUT DYNACOR

Dynacor is a dividend-paying industrial gold ore processor headquartered in Montreal, Canada. The corporation is engaged in gold production through the processing of ore purchased from the ASM (artisanal and small-scale mining) industry. At present, Dynacor operates in Peru, where its management and processing teams have decades of experience working with ASM miners. It also owns a gold exploration property (Tumipampa) in the Apurimac department.

The corporation intends to expand its processing operations in other jurisdictions as well.

Dynacor produces environmental and socially responsible gold through its PX IMPACT® gold program. A growing number of supportive firms from the fine luxury jewelry, watchmakers and investment sectors pay a small premium to our customer and strategic partner for this PX IMPACT® gold. The premium provides direct investment to develop health and education projects for our artisanal and small-scale miner’s communities.

Dynacor is listed on the Toronto Stock Exchange (DNG).

FORWARD-LOOKING INFORMATION

Certain statements in the preceding may constitute forward-looking statements, which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of Dynacor, or industry results, to be materially different from any future result, performance or achievement expressed or implied by such forward-looking statements. These statements reflect management’s current expectations regarding future events and operating performance as of the date of this news release.

Shares Outstanding: 38,572,507

Website: http://www.dynacor.com
Twitter: http://twitter.com/DynacorGold

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/482db361-25a0-4581-87a7-f0894c006213

PDF available: http://ml.globenewswire.com/Resource/Download/6d4d3203-3ae9-4631-a0e0-6aea406d86b2

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Inteleos to Host Roundtable on Advancing Maternal Health through Point-Of-Care-Ultrasound Certification6.5.2024 23:25:48 CEST | Press release

Global healthcare certification leader convenes experts to discuss ultrasound training and certification as key strategy to reduce maternal mortality ROCKVILLE, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, will host a roundtable discussion titled "Advancing Maternal and Fetal Health through POCUS Training and Certification" on May 29 alongside a side event during the WHO World Health Assembly and the AI for Good Global Summit. The roundtable will explore the urgent need to expand point-of-care ultrasound (POCUS) training and certification for frontline maternal health clinicians as a crucial intervention for reducing preventable maternal deaths and achieving UN Sustainable Development Goals, and how to implement to scale. Despite the increased availability of affordable ultrasound technology, there remains a significant training gap that limits access to this diagnostic tool, especially in low-resource areas with high matern

ETC’s Commercial/Industrial Units Awarded Three Contracts Totaling $15.9 Million6.5.2024 22:15:00 CEST | Press release

SOUTHAMPTON, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation’s (OTC Pink: ETCC) (“ETC” or the “Company”) Sterilization Systems Group announced it has been awarded $13.9 million in contracts from two multi-national medical device manufacturers. The contracts include four, sixteen pallet ethylene oxide (“EO”) sterilization system chambers with related conveyer systems, and a large capacity vacuum drying chamber with preconditioning. “These contracts reflect ETC Sterilization Systems Group’s dedication to innovation in our mechanical designs, control systems and software expertise to meet the challenging requirements of this market,” states Eric Hunnicutt, ETC Director of EO Sterilizer Sales. ETC’s Sterilization Systems Group offers Steam and Ethylene Oxide (“EO”) Sterilizer Systems, Vacuum Dryers, Software Systems, and project management services to the Medical Device, Pharmaceutical, Biotechnology, and Life Science industries. ETC’s systems are specially design

Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC6.5.2024 22:05:00 CEST | Press release

If approved, Zeno will be the first targeted therapy for NRG1+ cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) non-small cell lung (NSCLC) and NRG1+ pancreatic (PDAC) cancer. “FDA acceptance of our first BLA represents an important achievement for Merus and an important potential treatment opportunity for patients with NRG1+ cancer, a disease with poor prognosis and high unmet need,” said Dr. Andrew Joe, Chief Medical Officer at Merus. “Zenocutuzumab has the potential to be the first and only targeted therapy for patients with NRG1+ lung and

Nokia Corporation: Repurchase of own shares on 06.05.20246.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 06 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 06.05.2024 Espoo, Finland – On 06 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL385,6823.45CEUX--BATE--AQEU--TQEX--Total385,6823.45 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Trading in Novo Nordisk shares by board members, executives and associated persons6.5.2024 21:02:16 CEST | Press release

Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Novo Holdings A/S, associated to Kasim Kutay 2 Reason for the notification a) Position/status Member of the Board of Directors b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A&S b) LEI 549300DAQ1CVT6CXN342

HiddenA line styled icon from Orion Icon Library.Eye